Pharmaceutical product launches are becoming increasingly complex, particularly as companies navigate changing global pricing dynamics, payer scrutiny, artificial intelligence, and the unique challenges of rare disease commercialization. At the 2026 Life Sciences Product Launch Summit, speakers across the summit’s sessions repeatedly returned to one central message: successful launches are built long before a product reaches the market.
Across sessions focused on pricing, cross-functional preparation, Medical Affairs readiness, and rare disease strategy, industry leaders emphasized that evidence generation, payer engagement, patient identification, and organizational alignment can no longer wait until the months immediately preceding approval. Instead, many of these activities may need to begin 18 to 24 months or more before launch.
Global Pricing Is Reshaping Launch Strategy
Pricing strategy emerged as one of the most significant considerations for companies preparing new products for market. During a session on strategic pricing models, Nick Marchant, VP and Head of Value Access Strategy for Rare Disease and Internal Medicine Business Units at Pfizer, discussed how pricing decisions across international markets are becoming increasingly interconnected.
Marchant highlighted the importance of preparing evidence well in advance for European markets, carefully sequencing country launches, and understanding market-specific pricing mechanisms in countries including China and Japan. He also discussed the growing importance of Most-Favored-Nation pricing considerations, noting that companies increasingly need to think about U.S. and international pricing as components of a single global strategy rather than separate decisions.
Rare disease products are not insulated from these pressures. Madhav Vasanthavada, SVP and Chief Commercial Officer at Abeona Therapeutics, discussed the challenge of establishing value for innovative cell and gene therapies where established pricing benchmarks may not exist. For one-time treatments, manufacturers may need to demonstrate not only clinical value but also the costs that therapy could potentially offset compared with years of ongoing treatment.
That value narrative requires evidence, engagement with key opinion leaders, and communication with payers and patient advocacy organizations well before launch. Long payer approval processes for some cell and gene therapies make early engagement particularly important.
Cross-Functional Alignment Cannot Wait Until Launch
Another recurring theme was the need to align Medical Affairs, Commercial, and Market Access before a product reaches the market.
Lawrence Bressler, listed in the summit agenda as former VP of Marketing at Disc Medicine, described the concept as “Launch Synchrony.” Companies need to answer fundamental questions early, including who the target patient is, what evidence payers will require, how the product will be differentiated, and how the organization will communicate its value.
The infrastructure behind a launch also takes significant time to develop. Data systems, patient-identification capabilities, Centers of Excellence mapping, and other operational resources may require 18 to 24 months to establish. The challenge can be particularly pronounced for emerging biotechnology companies that do not have the infrastructure of larger pharmaceutical organizations.
Misalignment can create additional problems. When Commercial, Medical Affairs, and Access teams develop different positioning or priorities for the same product, healthcare professionals and patients ultimately encounter an inconsistent story. Speakers emphasized that major strategic decisions should therefore be made and operationalized before launch rather than resolved while a product is entering the market.
Medical Affairs Is Moving Earlier in the Launch Process
Medical Affairs was repeatedly positioned as a critical component of launch preparation.
William Soliman, PhD, BCMAS, Founder and CEO of the Accreditation Council for Medical Affairs, discussed several common weaknesses in launch readiness, including evidence generation beginning too late, insufficient KOL engagement, inconsistent internal processes, and clinical endpoints that may not fully align with what physicians or patient communities consider meaningful.
Data presented during the session also illustrated gaps in Medical Affairs preparation. According to the ACMA Medical Affairs Organizational Structure Survey of 30 companies presented by Soliman, 63% reported Medical Affairs involvement in Phase 1 through Phase 3 trial design, while 30% still excluded Medical Affairs from product development or new business committees. Additionally, 43% reported having no predefined learning and development team for Medical Affairs.
Soliman described launch readiness as progressing from fragmented activities performed reactively after approval to standardized processes that are coordinated, benchmarked, and evaluated consistently before launch. The broader message was that Medical Affairs should not simply support commercialization after approval. Its involvement can influence evidence generation, payer communication, KOL relationships, and ultimately how prepared an organization is when a product becomes available.
Rare Disease Requires a Different Commercialization Model
The differences between rare disease and broader pharmaceutical markets became especially clear during a panel featuring Ray Frost of Cogent Biosciences, Sabrina McGuigan of Sanofi, and Abhishek “Abi” Agrawal of GSK.
Rare disease commercialization often begins with finding the patients themselves. Because populations can be small and geographically dispersed, identifying Centers of Excellence, mapping treating physicians, understanding the patient journey, and educating healthcare professionals become foundational launch activities.
Those challenges are compounded by the diagnostic journey. Panelists discussed how patients with rare diseases may spend six to seven years seeking a diagnosis. Geographic barriers can further complicate identification, particularly when patients live far from specialized treatment centers and rely on primary care clinicians who may rarely encounter the disease.
Being first to market does not eliminate access challenges either. Payers may still require substantial evidence and prior authorization, and they may need education about the disease itself. Patient advocacy organizations can therefore play an important role in building disease awareness and helping companies better understand the needs of affected communities.
When panelists were asked where they would invest an additional dollar during a rare disease launch, all three independently pointed to Market Access, underscoring the importance they placed on ensuring that an approved therapy can ultimately reach the patients for whom it is intended.
AI Adds Another Layer to Launch Readiness
Artificial intelligence also surfaced as an emerging consideration for launch teams. Speakers noted that AI is already being incorporated into areas including clinical trial documentation, prior authorization workflows, claims and electronic medical record tools, real-world evidence platforms, drug development, and field-force enablement.
The opportunity comes with new organizational questions. Companies need governance frameworks that define how AI tools can be used responsibly and consistently, particularly as the technology becomes embedded across multiple functions involved in launch preparation.
The discussion also extended to how patients and healthcare professionals discover information. As AI-powered tools become another pathway for finding healthcare information, companies may need to consider how their disease education and scientific content can be found and understood across emerging search environments in addition to traditional digital channels.
Launch Excellence Is Increasingly an Organizational Capability
Taken together, the sessions at the Life Sciences Product Launch Summit suggested that launch success increasingly depends on what happens years before approval.
Pricing decisions can affect markets around the world. Medical Affairs needs to influence evidence strategy earlier. Market Access must engage payers before barriers emerge. Rare disease teams need to identify patients and treatment centers before Commercial begins outreach. And Commercial, Medical, and Access teams need to operate from a shared strategy rather than independent plans.
The science remains fundamental, but bringing that science successfully into the market requires an organization capable of translating evidence into value, coordinating stakeholders, anticipating access barriers, and building the necessary infrastructure well before launch day.
For life sciences companies preparing their next product launch, the message from the summit was consistent: launch readiness is no longer a final-stage activity. It is a long-term, cross-functional capability that begins years before the first patient receives treatment.
